Disorders Caused by Toxins

Slide 1 · Disorders Caused by Toxins

Botulinum neurotoxin · Curare · Neuromuscular transmission

Presynaptic toxin

Postsynaptic toxin

Dr Abu Suraih Sakhri

MBBS, MD (Pathology)

www.abusuraihsakhri.com

Slide 2 · Learning objectives

Localize neuromuscular dysfunction to the presynaptic terminal or postsynaptic endplate.

Explain how botulinum toxin interrupts acetylcholine release and produces flaccid paralysis.

Contrast botulinum toxin with curare and selected immune-mediated junction disorders.

Recognize urgent clinical consequences and the principles of confirmation and support.

Slide 3 · Why toxins belong in neuromuscular pathology

Transmission may fail even when nerve and muscle fibers remain anatomically present.

Biologic and plant-derived toxins reveal distinct vulnerable sites in the junction.

Clinical expression is predominantly painless weakness rather than sensory loss.

Motor axon terminal

ACh vesicles

ACh

Synaptic cleft

Muscle sarcolemma

Schematic

Presynaptic output

Postsynaptic reception

Slide 4 · Anatomy of the motor endplate

Motor axons terminate as presynaptic boutons on individual skeletal myofibers.

A synaptic cleft separates the axon terminal from the specialized sarcolemma.

Postsynaptic membrane folds concentrate acetylcholine receptors.

Motor axon terminal

ACh vesicles

ACh

Synaptic cleft

Muscle sarcolemma

Schematic

Slide 5 · The normal transmission sequence

A motor action potential reaches the nerve terminal.

Acetylcholine-containing vesicles release transmitter into the cleft.

Receptor activation generates a signal that initiates skeletal muscle contraction.

Motor impulse

Presynaptic ACh release

ACh receptor activation

Muscle contraction

Schematic

Slide 6 · Presynaptic boutons are secretory structures

Terminal swellings are positioned to release acetylcholine near the endplate.

The synaptic vesicle must fuse with the terminal membrane to release its contents.

Botulinum neurotoxin disables this exocytotic step.

Motor axon terminal

ACh vesicles

ACh

Synaptic cleft

Muscle sarcolemma

Toxin target

Schematic

Slide 7 · Acetylcholine must reach the receptor

Acetylcholine exits the motor terminal rather than crossing the cleft in vesicles.

The synaptic cleft is the extracellular space between bouton and sarcolemma.

Blockage before release deprives intact receptors of their ligand.

Vesicle fusion

ACh in synaptic cleft

Postsynaptic binding

Endplate response

Schematic

Slide 8 · Postsynaptic membrane specialization

ACh receptors cluster on folded regions of the muscle sarcolemma.

Spatial receptor organization supports efficient conversion of a chemical signal to contraction.

Curare acts at this receptor level rather than on synaptic vesicle fusion.

Motor axon terminal

ACh vesicles

ACh

Synaptic cleft

Muscle sarcolemma

Receptor target

Schematic

Slide 9 · The critical two-site distinction

Presynaptic failure: Insufficient transmitter becomes available in the cleft.

Postsynaptic failure: Available transmitter cannot produce a normal receptor response.

Both routes reduce neuromuscular activation and cause weakness.

Presynaptic lesion

Failure of acetylcholine delivery

Botulinum toxin

Postsynaptic lesion

Failure of acetylcholine reception

Curare

Slide 10 · Why weakness can be painless

The immediate defect concerns neuromuscular activation, not destruction of pain fibers.

Robbins groups neuromuscular junction disorders by painless weakness and fatigue.

A normal-appearing muscle does not exclude major transmission failure.

Impaired transmission

Reduced muscle activation

Weakness without primary pain

Schematic

Slide 11 · Three different causes of junction failure

Toxins directly interfere with transmitter release or receptor occupancy.

Autoantibodies impair presynaptic calcium-channel function or postsynaptic proteins.

Inherited defects alter junction proteins and produce congenital myasthenic syndromes.

Acquired toxic

Botulinum toxin

Curare

Other causes

Immune-mediated disease

Inherited protein defects

Slide 12 · Localization before disease naming

Ask whether the exposure affects the motor nerve terminal or endplate receptor.

Determine whether the resulting dysfunction reduces release or receptor effectiveness.

Use pattern of weakness, exposure history, and supportive testing to distinguish etiologies.

Clinical weakness

Identify possible exposure

Localize transmission defect

Select confirmatory work-up

Schematic

Slide 13 · Two principal agents in this lecture

Botulinum neurotoxin: A bacterial protein that inhibits acetylcholine release.

Curare: Plant-derived substances that antagonize acetylcholine receptors.

Both impair transmission and may produce flaccid paralysis by different mechanisms.

Botulinum neurotoxin

Bacterial exotoxin

Presynaptic effect

Curare

Plant-derived compounds

Postsynaptic effect

Slide 14 · Botulinum neurotoxin as a bacterial exotoxin

Botulinum toxin as a bacterial protein with a binding and an enzymatic component.

Its catalytic activity modifies proteins involved in neurotransmitter secretion.

The effect is functional synaptic blockade rather than obligatory neuronal death.

Toxin binds terminal

Active component enters

Exocytotic machinery disabled

ACh release inhibited

Schematic

Slide 15 · Microbiologic origin of botulism

The organism is an anaerobic, gram-positive, spore-forming bacillus.

Related toxin-producing clostridia can rarely cause similar clinical botulism.

The disease is attributable to biologically active botulinum neurotoxin.

C. Botulinum

Toxin-mediated neuromuscular paralysis

Slide 16 · Protein domains explain toxin specificity

A binding component directs the protein to susceptible nerve endings.

An enzymatic light-chain component modifies the transmitter-release apparatus.

Selectivity for synaptic machinery explains the characteristic physiologic deficit.

Binding / entry

Access to presynaptic terminal

Enzymatic injury

Cleavage of vesicle-fusion proteins

Slide 17 · Botulism is not a single exposure pathway

Preformed toxin can be consumed in contaminated food.

Clostridial growth in wounds can generate toxin within the host.

Intestinal colonization and excessive therapeutic or cosmetic exposure are additional routes.

Foodborne

Wound-associated

Intestinal colonization

Iatrogenic

Schematic

Slide 18 · Foodborne botulism: Preformed toxin

The relevant exposure is ingestion of toxin already present in food.

A food-linked history may connect multiple symptomatic individuals.

Systemic effects ultimately reflect inhibition of neuromuscular transmission.

Contaminated food

Absorbed neurotoxin

Presynaptic blockade

Descending weakness

Schematic

Slide 19 · Wound botulism: Local production, systemic effect

Organisms in an infected wound can produce botulinum neurotoxin.

Toxin reaches distant nerve terminals and acts outside the wound.

The extent of paralysis does not require destructive infection of skeletal muscles.

Contaminated wound

Local toxin production

Neural terminal exposure

Flaccid paralysis

Schematic

Slide 20 · Intestinal colonization botulism

In infant botulism, ingested spores can colonize the immature intestine.

Toxin production in the gut precedes neuromuscular effects.

The intestinal pathway differs mechanistically from consuming preformed toxin.

Foodborne intoxication

Toxin already in food

Ingestion of active toxin

Infant colonization

Spores colonize intestine

Toxin generated in vivo

Slide 21 · Iatrogenic botulism: Systemic toxicity after use

Botulinum toxin is also used intentionally for local muscular effects.

Systemic spread after injection can produce a syndrome resembling natural botulism.

The mechanism remains presynaptic interruption of acetylcholine release.

Therapeutic intent

Localized selected-muscle effect

Unwanted toxicity

Excessive or distant neuromuscular weakness

Slide 22 · Motor nerve terminals are the principal target

Botulinum neurotoxin reaches cholinergic presynaptic endings.

The target is the apparatus that releases acetylcholine into the motor endplate cleft.

The postsynaptic acetylcholine receptor is not directly blocked by botulinum toxin.

Motor axon terminal

ACh vesicles

ACh

Synaptic cleft

Muscle sarcolemma

Toxin target

Schematic

Slide 23 · Initial binding to presynaptic membranes

Toxin binding to gangliosides on motor neurons.

Neuronal surface recognition initiates toxin entry into the cell.

Binding specificity helps explain why neural secretion is the key affected function.

Ganglioside binding

Toxin uptake

Intracellular catalytic action

Schematic

Slide 24 · Internalization precedes intracellular cleavage

Surface attachment alone does not explain sustained functional inhibition.

Following entry, the toxin’s catalytic component reaches the neuronal cytoplasm.

The functional target is the protein machinery governing synaptic vesicle fusion.

Surface binding

Internalization

Catalytic component translocation

Protein cleavage

Schematic

Slide 25 · SNARE proteins couple vesicles to the membrane

Synaptobrevin (VAMP), SNAP-25, and syntaxin participate in exocytotic fusion.

The assembled fusion apparatus allows vesicles to discharge transmitter.

Cleaving a required component stops efficient acetylcholine release.

Intact SNARE system

Vesicle fusion proceeds

Cleaved SNARE system

ACh exocytosis fails

Slide 26 · The serotype matters for the exact substrate

Synaptobrevin is one of several SNARE protein substrates.

Different botulinum neurotoxin serotypes target different SNARE proteins.

The shared endpoint is blockade of transmitter-containing vesicle fusion.

Illustrative toxin serotype

Established protein target

A / E

SNAP-25

B / D / F / G

Synaptobrevin (VAMP)

C

Syntaxin and SNAP-25

Slide 27 · Blocked fusion means blocked transmitter release

A vesicle may remain intact but cannot efficiently merge with the nerve terminal membrane.

Consequently less acetylcholine enters the synaptic cleft.

Muscle receptor activation falls despite the receptor itself remaining the indirect target.

Motor axon terminal

ACh vesicles

ACh

Synaptic cleft

Muscle sarcolemma

Toxin target

Schematic

Slide 28 · From the molecule to the patient’s weakness

SNARE protein cleavage reduces acetylcholine output.

Insufficient endplate activation prevents reliable muscle contraction.

The clinical phenotype is a flaccid, motor-predominant paralytic illness.

SNARE cleavage

ACh release ↓

Endplate response ↓

Flaccid paralysis

Schematic

Slide 29 · Flaccid paralysis is a functional consequence

A contracting muscle requires successful neurotransmission.

In botulism, chemical communication from motor axon to myofiber is interrupted.

This differs from direct necrosis or primary inflammatory destruction of myofibers.

Neurotransmission defect

ACh unavailable

Contractile trigger fails

Primary muscle destruction

Myofiber injury

Different histologic substrate

Slide 30 · Botulism versus tetanus: Shared family, opposite pattern

Both toxins inhibit neurotransmitter release, as Chapter 8.

Botulinum toxin blocks acetylcholine release at the motor endplate.

Tetanus toxin blocks inhibitory neurotransmission and produces spastic paralysis.

Botulism

Peripheral motor terminal

Flaccid paralysis

Tetanus

Inhibitory pathways affected

Spastic paralysis

Slide 31 · Anatomic target predicts paralysis phenotype

Direct loss of excitatory drive to skeletal muscle produces flaccidity.

Loss of inhibitory control over motor neurons instead creates excessive activation.

The direction of synaptic effect is more informative than the bacterial genus alone.

Targeted synapse

Altered neurotransmission

Characteristic motor phenotype

Schematic

Slide 32 · Severe dysfunction can lack specific histology

Neuropathologic changes in botulinum and tetanus toxicity may be subtle and nonspecific.

Absence of a diagnostic structural lesion does not exclude a profound functional blockade.

The diagnosis therefore depends heavily on clinical features and toxin-specific investigations.

Function ≠ morphology

Severe paralysis may coexist with nonspecific tissue findings

Slide 33 · The recognizable descending motor pattern

Botulism typically begins with cranial nerve dysfunction.

Weakness may then extend to neck, trunk, and extremities.

Progression can involve upper airway and respiratory muscles.

Cranial nerve palsies

Bulbar / neck weakness

Limb weakness

Respiratory compromise

Schematic

Slide 34 · Ocular and facial weakness direct attention to the junction

Diplopia, ptosis, or other cranial nerve palsies can precede generalized weakness.

Cranial findings should prompt examination of speech, swallowing, and breathing.

The phenotype alone is not pathognomonic: Immune junction disorders overlap.

Cranial involvement

Ocular movement

Facial strength

Bulbar involvement

Speech

Swallowing and airway safety

Slide 35 · Bulbar dysfunction can threaten the airway

Dysarthria, dysphagia, nasal voice, and poor secretion handling imply bulbar impairment.

Aspiration risk and upper-airway obstruction may develop before overt diaphragmatic failure.

Serial clinical assessment is essential when weakness progresses.

Bulbar weakness

Poor swallow / cough

Aspiration or airway threat

Schematic

Slide 36 · Autonomic symptoms add diagnostic clues

Botulinum toxin can impair cholinergic autonomic transmission.

Dry mouth, constipation or ileus, and urinary retention are relevant examination findings.

These features should be interpreted with cranial and motor abnormalities, not in isolation.

Somatic motor effects

Cranial weakness

Limb/respiratory weakness

Autonomic effects

Dry mouth / dry eyes

Urinary and bowel dysfunction

Slide 37 · Respiratory failure is the principal immediate threat

Weakness of respiratory muscles compromises ventilation.

Bulbar dysfunction may independently undermine airway protection.

Respiratory muscle involvement as a potentially fatal consequence.

Ventilatory pump

Diaphragm and chest muscle strength

Airway protection

Bulbar and swallowing function

Slide 38 · A mechanism-to-symptom map

Blocked acetylcholine release impairs muscle activation.

Cranial and bulbar dysfunction produces ocular, speech, and swallowing abnormalities.

More extensive blockade can produce limb and breathing-muscle weakness.

ACh exocytosis inhibited

Multiregional weakness

Respiratory/airway danger

Schematic

Slide 39 · Clinical recognition precedes laboratory proof

Consider botulism in progressive descending flaccid weakness with cranial neuropathies.

Exposure history narrows the possibilities but may initially be unavailable.

Laboratory confirmation is valuable; Urgent treatment decisions are clinical.

Recognize pattern

Examine airway and respiration

Notify experts / public health

Confirm when feasible

Schematic

Slide 40 · A focused bedside neurologic examination

Document cranial nerve, facial, palate, tongue, speech, and swallowing function.

Grade limb and neck strength repeatedly, not just on presentation.

Reassess respiratory effort and autonomic dysfunction as the course evolves.

Domain

Priority finding

Cranial/bulbar

Eye movements, voice, swallow

Motor

Neck and limb strength

Respiratory

Effort, ventilation, airway

Autonomic

Dryness, bowel, urinary function

Slide 41 · Serial respiratory assessment is more informative

Respiratory decline may occur during observation even after mild initial weakness.

Track clinical work of breathing together with objective measures where feasible.

Facial weakness can impair the mouth seal needed for conventional spirometry.

Baseline examination

Serial strength/respiratory checks

Escalate support if worsening

Schematic

Slide 42 · Toxin detection confirms a clinical hypothesis

Specialized laboratories may test serum, stool, gastric contents, or implicated food for toxin.

Culture-based testing may identify toxin-producing clostridia in selected specimens.

Testing must be coordinated with expert public health laboratories.

Evidence source

Diagnostic purpose

Serum / stool

Toxin detection

Wound material

Organism identification

Implicated food

Exposure-source confirmation

Slide 43 · Specimen collection must not delay treatment

Serum is ideally obtained before antitoxin administration.

Confirmation may take days and may be negative in genuine cases.

Clinical urgency outweighs waiting for a laboratory report.

Clinical suspicion

Collect suitable samples promptly

Administer indicated antitoxin

Schematic

Slide 44 · Antitoxin addresses circulating toxin

The therapeutic objective is to neutralize toxin not yet bound to its neural target.

It prevents additional progression more effectively than it reverses established blockade.

Specialist consultation and prompt administration are emphasized by CDC guidance.

Before neuronal binding

Antitoxin can neutralize

Progression may be limited

After intracellular action

Established blockade persists

Supportive care remains essential

Slide 45 · Supportive care bridges the impaired transmission

Airway and ventilatory support can be life-saving while paralysis resolves.

Dysphagia requires careful attention to aspiration and nutrition.

Progressive bulbar or respiratory weakness warrants high-acuity monitoring.

Recognize danger

Protect airway

Provide ventilation if required

Monitor recovery

Schematic

Slide 46 · Infant botulism is a distinct treatment pathway

Infant intestinal colonization produces toxin within the gut.

Clinical suspicion requires prompt consultation; Do not wait for laboratory confirmation.

Specific human-derived botulism immune globulin is used for eligible infant cases in the United States.

Infant botulism

Intestinal toxemia

Human immune globulin (BabyBIG)

Other symptomatic botulism

Exposure routes differ

Equine-derived antitoxin in US guidance

Slide 47 · Teaching vignette: Food-associated paralysis

An adult develops diplopia, slurred speech, and progressive symmetric weakness after a shared meal.

A second person who ate the same food is similarly affected.

Question: Which junctional step best explains the syndrome?

Discussion point

Presynaptic ACh exocytosis is inhibited

Illustrative case — not a patient report

Slide 48 · Reason through the foodborne vignette

A clustered exposure makes ingested toxin a plausible explanation.

Cranial nerve involvement plus descending weakness supports botulism.

Prioritize respiratory assessment, public-health consultation, and time-sensitive antitoxin evaluation.

Shared food exposure

Cranial weakness

Botulism suspected

Urgent respiratory + antitoxin pathway

Schematic

Slide 49 · Curare: The contrasting postsynaptic toxin

Curare refers to plant-derived muscle-relaxing substances.

Its principal toxic action at the junction is blockade of acetylcholine receptors.

The result is ineffective neuromuscular transmission and flaccid paralysis.

Motor axon terminal

ACh vesicles

ACh

Synaptic cleft

Muscle sarcolemma

Receptor target

Schematic

Slide 50 · Historical curare and the motor endplate

Robbins recounts curare use as an arrow poison by Indigenous communities of the Amazon.

The observation that exposure produced paralysis helped identify receptor-level physiology.

Its history is distinct from the mechanism of a bacterial neurotoxin.

Historical use

Plant-derived arrow poisons

Observed paralytic effect

Mechanistic insight

Postsynaptic receptor blockade

Failure of muscle activation

Slide 51 · Receptor blockade without transmitter suppression

A motor neuron may continue releasing acetylcholine into the cleft.

Curare prevents normal activation of endplate acetylcholine receptors.

Therefore, the key deficit is ligand response rather than presynaptic release.

Presynaptic function

ACh may be released

Vesicle fusion not primary target

Postsynaptic function

Receptor occupied/blocked

Normal endplate response fails

Slide 52 · Why curare causes flaccid paralysis

The postsynaptic receptor must be activated for a normal muscle response.

Occupancy by a blocking antagonist interrupts that signal.

The muscle remains functionally disconnected from an otherwise activated motor nerve.

ACh receptor blocked

Endplate response reduced

Flaccid paralysis

Schematic

Slide 53 · Curare and medical neuromuscular blockers

Historical use of curare as a surgical muscle relaxant.

Modern agents with a related receptor-blocking mechanism replaced it in routine practice.

Controlled anesthesia use and unintended neuromuscular toxicity should not be equated.

Historical curare

Plant-derived agent

Obsolete surgical use

Modern clinical analogy

Pharmacologic receptor blockade

Managed in anesthetic care

Slide 54 · Compare curare with botulinum toxin directly

Botulinum toxin: Failed acetylcholine liberation from the motor terminal.

Curare: Failed acetylcholine recognition at the endplate receptor.

Both can leave downstream muscle activation insufficient.

Characteristic

Botulinum toxin

Curare

Origin

Bacterial neurotoxin

Plant-derived compounds

Primary site

Presynaptic

Postsynaptic

Molecular effect

Inhibits vesicle exocytosis

Blocks ACh receptors

Motor result

Flaccid paralysis

Flaccid paralysis

Slide 55 · Myasthenia gravis shares a postsynaptic location

ACh receptor autoantibodies reduce receptor availability and function.

Curare blocks receptor function through a nonimmune toxic mechanism.

Myasthenic weakness commonly fluctuates with exertion and may affect ocular muscles.

Myasthenia gravis

Autoimmune receptor dysfunction

Fluctuating, fatigable weakness

Curare

Direct receptor blockade

Toxic/pharmacologic exposure

Slide 56 · Lambert–Eaton shares a presynaptic location

Lambert–Eaton syndrome impairs ACh release by targeting presynaptic calcium channels.

Botulinum neurotoxin impairs later vesicle-fusion machinery.

Strength often improves with brief repeated activity in Lambert–Eaton syndrome.

Lambert–Eaton

Immune calcium-channel defect

Facilitation with activity

Botulinum neurotoxin

SNARE cleavage

Exposure-related paralysis

Slide 57 · Same compartment does not mean same mechanism

At the presynaptic terminal, ion-channel dysfunction differs from vesicle-fusion blockade.

At the postsynaptic membrane, antibody-mediated receptor loss differs from receptor antagonism.

Etiology, trajectory, and exposure history remain essential to diagnosis.

Compartment

Immune disorder

Toxic disorder

Presynaptic

Lambert–Eaton (Ca²⁺ channels)

Botulinum toxin (exocytosis)

Postsynaptic

Myasthenia gravis (AChR / MuSK)

Curare (AChR blockade)

Slide 58 · Distinguish botulism from other acute weakness

Guillain–Barré syndrome and myasthenia gravis may overlap clinically with botulism.

A descending cranial-onset pattern and relevant exposure history support botulism.

No single symptom replaces comprehensive neurologic examination or appropriate testing.

Botulism clues

Cranial-onset descending weakness

Exposure / outbreak connection

Competing diagnoses

Other junction disorders

Acute neuropathic weakness

Slide 59 · A mechanistic diagnostic map

Begin with the phenotype: Painless flaccid weakness and the affected motor regions.

Assess toxic exposure, immune features, familial onset, and progression.

Use electrophysiology, serology, or toxin testing as appropriate to the working diagnosis.

Painless weakness

Toxic vs immune vs inherited

Pre- vs postsynaptic localization

Targeted investigations

Schematic

Slide 60 · Clinical pitfall: Normal morphology is not reassurance

Botulinum-associated pathology may show only subtle nonspecific changes.

Diagnosis is not ruled out by a structurally unremarkable muscle biopsy.

Mechanistic interpretation and respiratory surveillance can matter more than routine histology.

Transmission can fail

Even without a specific histopathologic signature

Slide 61 · Clinical pitfall: Do not await definitive tests

Suspected botulism is a clinical and public-health emergency.

Laboratory studies support diagnosis and investigation but results may lag.

Early expert consultation, antitoxin evaluation, and monitoring must proceed in parallel.

Clinical suspicion

Immediate clinical action

Testing in parallel

Schematic

Slide 62 · Teaching vignette: Postsynaptic blockade

During a controlled anesthetic procedure, a muscle relaxant prevents movement despite motor stimulation.

Presynaptic transmitter release is not the intended target.

Question: Which functional compartment is blocked?

Discussion point

Postsynaptic nicotinic ACh receptor

Illustrative pharmacology scenario

Slide 63 · Explain the postsynaptic vignette

Receptor antagonism impairs the endplate response despite available acetylcholine.

The physiologic analogy is curare rather than botulinum toxin.

This distinction separates pharmacologic motor paralysis from presynaptic neurotoxic exocytosis failure.

Transmitter present

ACh receptors blocked

Endplate inactive

Muscle relaxation

Schematic

Slide 64 · Two toxins, two molecular targets, one motor outcome

Botulinum neurotoxin cleaves secretory machinery and prevents ACh exocytosis.

Curare prevents ACh receptor activation at the muscle membrane.

Both culminate in deficient neuromuscular activation and flaccid weakness.

Motor axon terminal

ACh vesicles

ACh

Synaptic cleft

Muscle sarcolemma

Schematic

No ACh released

ACh cannot activate receptor

Slide 65 · Five facts that should survive the lecture

The neuromuscular junction transduces motor-neuron activity into muscle contraction.

Botulism is a toxin-mediated presynaptic exocytosis disorder.

Curare produces postsynaptic ACh receptor blockade.

Flaccid paralysis can be severe without characteristic tissue destruction.

Botulism requires rapid clinical recognition and respiratory-risk evaluation.

Slide 66 · Apply the localization rule

If acetylcholine cannot enter the cleft, focus on the presynaptic release apparatus.

If transmitter is released but its receptor cannot be activated, focus on the endplate.

Presynaptic vs postsynaptic localization organizes toxin mechanisms and important differentials.

No transmitter delivered

Botulinum toxin

Presynaptic fusion defect

Transmitter not received

Curare

Postsynaptic receptor defect

Slide 67 · Primary and supplementary references

Robbins, Cotran & Kumar. Pathologic Basis of Disease. 11th ed. (2026). Ch. 27, pp. 1115–1116; Ch. 8, pp. 311, 346.

Rao AK et al. Clinical Guidelines for Diagnosis and Treatment of Botulism, 2021. MMWR Recomm Rep. 70(2):1–30.

CDC. Clinical Overview of Infant Botulism. Updated September 29, 2026.

Rossetto O et al. The metallo-proteinase activity of tetanus and botulism neurotoxins. J Physiol Paris. 1995;89:43–50.